$7.56
3.69%
Nasdaq, Sep 09, 07:48 pm CET
ISIN
US98422E1038
Symbol
XERS

Xeris Biopharma Holdings Stock price

$7.85
+2.37 43.25% 1M
+4.08 108.22% 6M
+4.46 131.56% YTD
+5.32 210.28% 1Y
+6.07 341.01% 3Y
+3.37 75.22% 5Y
-12.37 61.18% 10Y
-12.37 61.18% 20Y
Nasdaq, Closing price Fri, Sep 05 2025
-0.04 0.51%
ISIN
US98422E1038
Symbol
XERS
Industry

Key metrics

Basic
Market capitalization
$1.3b
Enterprise Value
$1.4b
Net debt
$159.3m
Cash
$59.3m
Shares outstanding
161.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
5.1 | 4.3
EV/Sales
5.8 | 4.9
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-9.2%
Return on Equity
185.2%
ROCE
-4.1%
ROIC
-3.4%
Debt/Equity
-11.3
Financials (TTM | estimate)
Revenue
$246.0m | $292.2m
EBITDA
$1.0m | $35.0m
EBIT
$-9.8m | $18.9m
Net Income
$-32.0m | $-11.0m
Free Cash Flow
$-16.8m
Growth (TTM | estimate)
Revenue
35.6% | 43.9%
EBITDA
103.9% | 253.7%
EBIT
73.6% | 156.3%
Net Income
46.3% | 80.0%
Free Cash Flow
56.8%
Margin (TTM | estimate)
Gross
82.2%
EBITDA
0.4% | 12.0%
EBIT
-4.0%
Net
-13.0% | -3.8%
Free Cash Flow
-6.8%
More
EPS
$-0.2
FCF per Share
$-0.1
Short interest
8.6%
Employees
394
Rev per Employee
$520.0k
Show more

Is Xeris Biopharma Holdings a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

Xeris Biopharma Holdings Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Xeris Biopharma Holdings forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a Xeris Biopharma Holdings forecast:

Buy
83%
Hold
17%

Financial data from Xeris Biopharma Holdings

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
246 246
36% 36%
100%
- Direct Costs 44 44
48% 48%
18%
202 202
33% 33%
82%
- Selling and Administrative Expenses 174 174
13% 13%
71%
- Research and Development Expense 28 28
11% 11%
11%
1.02 1.02
104% 104%
0%
- Depreciation and Amortization 11 11
0% 0%
4%
EBIT (Operating Income) EBIT -9.82 -9.82
74% 74%
-4%
Net Profit -32 -32
46% 46%
-13%

In millions USD.

Don't miss a Thing! We will send you all news about Xeris Biopharma Holdings directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Xeris Biopharma Holdings Stock News

Positive
Seeking Alpha
4 days ago
Xeris Biopharma delivered record Q2 revenue, driven by Recorlev's rapid adoption, and is on track to achieve breakeven in Q3. Recorlev is the primary growth engine, while Gvoke provides steady diversification; Keveyis' contribution is expected to continue declining. XP-8121, a once-weekly levothyroxine, offers significant long-term upside but introduces future funding risks for Phase 3 trials.
Neutral
Business Wire
15 days ago
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced the U.S Patent and Trademark Office has issued patent number 12,377,096 to the Company for Recorlev® (levoketoconazole) and that this patent is now...
Neutral
Seeking Alpha
about one month ago
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate Communications John P. Shannon - CEO & Director Steven M.
More Xeris Biopharma Holdings News

Company Profile

Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL.

Head office United States
CEO John Shannon
Employees 394
Founded 2005
Website www.xerispharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today